Effects of coenzyme Q10 in conjunction with vitamin e on retinal-evoked and cortical-evoked responses in patients with open-angle glaucoma

Journal of Glaucoma

Volumn 23, Issue 6, 2014, Pages 391-404

  Parisi, Vincenzo ^a   Centofanti, Marco ^a,b   Gandolfi, Stefano ^d   Marangoni, Dario ^c   Rossetti, Luca ^e   Tanga, Lucia ^a   Tardini, Mariagrazia ^d   Traina, Salvatore ^c   Ungaro, Nicola ^d   Vetrugno, Michele ^f   Falsini, Benedetto ^c  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e SAN PAOLO HOSPITAL   (Italy)

^f UNIVERSITY OF BARI   (Italy)

Author keywords

coenzyme Q10; glaucoma; PERG; VEP

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; TOCOFERSOLAN; UBIDECARENONE; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; EYE DROPS; UBIQUINONE;

ADULT; ARTICLE; CENTRAL CORNEAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVOKED CORTICAL RESPONSE; EVOKED VISUAL RESPONSE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MEDICATION COMPLIANCE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; RETINAL EVOKED RESPONSE; SENSORY NERVE CONDUCTION; SIGNAL NOISE RATIO; VISUAL ACUITY; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG EFFECTS; ELECTRORETINOGRAPHY; FEMALE; GLAUCOMA, OPEN-ANGLE; MALE; MIDDLE AGED; OCULOPLETHYSMOGRAPHY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RETINA GANGLION CELL; TOPICAL DRUG ADMINISTRATION; VISUAL CORTEX;

ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; ELECTRORETINOGRAPHY; EVOKED POTENTIALS, VISUAL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RETINAL GANGLION CELLS; TONOMETRY, OCULAR; UBIQUINONE; VISUAL CORTEX; VITAMIN E;

EID: 84905493321     PISSN: 10570829     EISSN: 1536481X     Source Type: Journal    
DOI: 10.1097/IJG.0b013e318279b836     Document Type: Article

References (54)

1. Holopigian K, Sieple W, Mayron C, et al. Electrophysiological and psychophysical flicker sensitivity in patients with primary open angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci. 1990;31:1863-1869.
2. Porciatti V, Falsini B, Brunori S, et al. Pattern electroretinogram as a function of spatial frequency in ocular hypertension and early glaucoma. Doc Ophthalmol. 1987;65:349-355.
3. Bach M, Speidel-Fiaux A. Pattern electroretinogram in glaucoma and ocular hypertension. Doc Ophthalmol. 1989;73: 173-181.
4. Ventura LM, Porciatti V, Ishida K, et al. Pattern electroretinogram abnormality and glaucoma. Ophthalmology. 2005; 112:10-19.
5. Hood DC, Xu L, Thienprasiddhi P, et al. The pattern electroretinogram in glaucoma patients with confirmed visual field deficits. Invest Ophthalmol Vis Sci. 2005;46:2411-2418.
6. Parisi V, Manni G, Centofanti M, et al. Correlation between optical coherence tomography, pattern electroretinogram and visual evoked potentials in open angle glaucoma patients. Ophthalmology. 2001;108:905-912.
7. Parisi V. Neural conduction in the visual pathways in ocular hypertension and glaucoma. Graefes Arch Clin Exp Ophthalmol. 1997;235:136-146.
8. Bray LC, Mitchell KW, Howe JW, et al. Visual function in glaucoma: a comparative evaluation of computerized static perimetry and the pattern visual evoked potential. Clin Vis Sci. 1992;7:21-29.
9. Parisi V, Bucci MG. Visual evoked potentials after photostress in patients with primary open-angle glaucoma and ocular hypertension. Invest Ophthalmol Vis Sci. 1992;33:436-442.
10. Horn FK, Jonas JB, Budde WM, et al. Monitoring glaucoma progression with visual evoked potentials of the blue-sensitive pathway. Invest Ophthalmol Vis Sci. 2002;43:1828-1834.
11. Horn FK, Bergua A, Junemann A, et al. Visual evoked potentials under luminance contrast and color contrast stimulation in glaucoma diagnosis. J Glaucoma. 2000;9: 428-437.
12. Falsini B, Colotto A, Porciatti V, et al. Follow-up study with pattern ERG in ocular hypertension and glaucoma patients under timolol maleate treatment. Clin Vis Sci. 1992;7: 341-347.
13. Ventura L, Porciatti V. Restoration of retinal ganglion cell function in early glaucoma after intraocular pressure reduction. Ophthalmology. 2005;1:20-27.
14. Papst N, Bopp M, Schnaudigel OE. The pattern evoked electroretinogram associated with elevated intraocular pressure. Graefes Arch Clin Exp Ophthalmol. 1984;222:34-37.
15. Arden GB, O'Sullivan F. Longitudinal follow up of glaucoma suspects tested with pattern electroretinogram. Bull Soc Belge Ophtalmol. 1992;244:147-154.
16. Nesher R, Trick GL, Kass MA, et al. Steady-state pattern electroretinogram following long term unilateral administration of timolol to ocular hypertensive subjects. Doc Ophthalmol. 1990;75:101-109.
17. Colotto A, Salgarello T, Giudiceandrea A, et al. Pattern electroretinogram in treated ocular hypertension: a crosssectional study after timolol maleate therapy. Ophthalmic Res. 1995;27:168-177.
18. Parisi V, Colacino G, Milazzo G, et al. Effects of nicergoline on the retinal and cortical electrophysiological responses in glaucoma patients: a preliminary open study. Pharmacol Res. 1999;40:249-255.
19. Parisi V, Manni GL, Colacino G, et al. Cytidine-50-diphosphocholine (citicoline) improves retinal and cortical responses in patients with glaucoma. Ophthalmology. 1999;106: 1126-1134.
20. Parisi V. Electrophysiological assessment of glaucomatous visual dysfunction during treatment with cytidine-50-diphosphocholine (citicoline): a study of 8 years of follow-up. Doc Ophthalmol. 2005;110:91-102.
21. Parisi V, Coppola G, Centofanti M, et al. Evidence of the neuroprotective role of citicoline in glaucoma patients. Prog Brain Res. 2008;173:541-554.
22. Falsini B, Marangoni D, Salgarello T, et al. Effect of epigallocatechin-gallate on inner retinal function in ocular hypertension and glaucoma: a short-term study by pattern electroretinogram. Graefes Arch Clin Exp Ophthalmol. 2009;247:1223-1233.
23. Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog Retin Eye Res. 2006;25: 490-513.
24. Nucci C, Tartaglione R, Cerulli A, et al. Retinal damage caused by high intraocular pressure-induced transient ischemia is prevented by coenzyme Q10 in rat. Int Rev Neurobiol. 2007;82:397-406.
25. Guo L, Cordeiro MF. Assessment of neuroprotection in the retina with DARC. Prog Brain Res. 2008;173:437-450.
26. Schober MS, Chidlow G, Wood JP, et al. Bioenergetic-based neuroprotection and glaucoma. Clin Experiment Ophthalmol. 2008;36:377-385.
27. Parisi V, Scarale ME, Balducci N, et al. Electrophysiological detection of delayed post-retinal neural conduction in human amblyopia. Invest Ophthalmol Vis Sci. 2010;51:5041-5048.
28. Parisi V, Miglior S, Manni G, et al. Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma. Ophthalmology. 2006;113:216-228.
29. Fiorentini A, Maffei L, Pirchio M, et al. The ERG in response to alternating gratings in patients with diseases of the peripherheral visual pathway. Invest Ophthalmol Vis Sci. 1981;21:490-493.
30. Hawlina M, Konec B. New non-corneal HK-loop electrode for clinical electroretinography. Doc Ophthalmol. 1992;81:253-259.
31. Porciatti V, Falsini B. Inner retina contribution to the flicker electroretinogram: a comparison with the pattern electroretinogram. Clin Vis Sci. 1993;8:435-447.
32. Jasper HH. The ten-twenty electrode system of the international federation of electroencephalography. Electronceph Clin Neurophysiol. 1958;10:371-375.
33. Celesia GC, Kaufmann D. Pattern ERG and visual evoked potentials in maculopathies and optic nerve disease. Invest Ophthalmol Vis Sci. 1985;26:726-735.
34. Parisi V, Coppola G, Ziccardi L, et al. Cytidine-50-diphosphocholine (citicoline): a pilot study in patients with non-arteritic ischaemic optic neuropathy. Eur J Neurol. 2008;15:465-474.
35. Parisi V, Tedeschi M, Gallinaro G, et al. CARMIS Study Group. Carotenoids and antioxidants in age-related maculopathy Italian study: multifocal electroretinogram modifications after one year. Ophthalmology. 2008;115:324-333.
36. Quigley HA, Sanchez RM, Dunkelberger GR, et al. Chronic glaucoma selectively damages large optic nerve fibers. Invest Ophthalmol Vis Sci. 1987;28:913-920.
37. Quigley HA, Dunkelberger GR, Green WR. Chronic human glaucoma causing selectively greater loss of large optic nerve fibers. Ophthalmology. 1988;95:357-363.
38. Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995; 36:774-786.
39. Orzalesi N, Miglior S, Lonati C, et al. Microperimetry of localized retinal nerve fiber layer defects. Vis Res. 1998;38: 763-771.
40. Shuman JS, Hee MR, Puliafito CA, et al. Quantification of nerve layer thickness in normal and glaucomatous eyes using optical coherence tomography. Arch Ophthalmol. 1995; 113:586-596.
41. Falsini B, Colotto A, Porciatti V, et al. Macular flicker-and pattern ERGs are differently affected in ocular hypertension and glaucoma. Clin Vis Sci. 1991;6:422-429.
42. Holopigian K, Seiple W, Greenstein VC. Electrophysiological evidence for outer retinal deficits in primary open angle glaucoma. Invest Ophthalmol Vis Sci. 1993;34(suppl):1269.
43. Holder GE. The pattern electroretinogram in anterior visual pathways dysfunction and its relationship to the pattern visual evoked potential: a personal clinical review of 743 eyes. Eye. 1997;11:924-934.
44. Viswanathan S, Frishman LJ, Robson JG. The uniform field and pattern ERG in macaques with experimental glaucoma: removal of spiking activity. Invest Ophthalmol Vis Sci. 2000;41:2797-2810.
45. Quinzii CM, Hirano M. Coenzyme Q and mitochondrial disease. Dev Disabil Res Rev. 2010;16:183-188.
46. Duchen MR. Mitochondria and calcium: from cell signalling to cell death. J Physiol. 2000;529:57-68.
47. Patel M, Day BJ, Crapo JD, et al. Requirement for superoxide in excitotoxic cell death. Neuron. 1996;16:345-355.
48. Beal MF. Coenzyme Q10 administration and its potential for treatment of neurodegenerative diseases. Biofactors. 1999;9: 261-266.
49. Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Curr Opin Clin Nutr Metab Care. 2005;8:641-646.
50. Parisi V. Impaired visual function in glaucoma. Clin Neurophysiol. 2001;112:351-458.
51. Gupta N, Yucel YH. Brain changes in glaucoma. Eur J Ophthalmol. 2003;suppl 3:S32-S35.
52. Yucel YH, Zhang Q, Weinreb RN, et al. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog Retin Eye Res. 2003;22:465-481.
53. Chaturvedi N, Hedley-Whyte T, Dreyer EB. Lateral geniculate nucleus in glaucoma. Am J Ophthalmol. 1993;116:182-188.
54. Fato R, Bergamini C, Leoni S, et al. Coenzyme Q10 vitreous levels after administration of coenzyme Q10 eyedrops in patients undergoing vitrectomy. Acta Ophthalmol. 2010;88: 150-151.